Volume 29, Number 5—May 2023
Research
Misdiagnosis of Clostridioides difficile Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019–20201
Table 5
Comparison between inpatients who had a stool specimen collected for CDI testing and inpatients who did not among incident diarrhea cases enrolled before COVID-19 pause (n = 1,283) in study of misdiagnosis of CDI by SOC specimen collection and testing among hospitalized adults, Louisville, Kentucky, USA, October 14, 2019–April 11, 2020*
Characteristic | Study stool specimen collected, n = 1,047 | Study stool specimen not collected, n = 236 |
p value |
---|---|---|---|
Demographics | |||
Median age, y (IQR) | 68 (61–78) | 67.5 (60–77) | 0.46 |
Female sex | 595 (56.8) | 146 (61.9) | 0.16 |
Black | 218 (21.5) | 81 (34.8) | <0.01 |
Hispanic |
18 (1.8) |
2 (0.9) |
0.33 |
Signs and symptoms | |||
Abdominal pain | 283 (28.7) | 53 (23.8) | 0.14 |
Fever | 109 (10.7) | 18 (7.8) | 0.18 |
Blood or pus in stool |
90 (9.3) |
20 (9.0) |
0.91 |
Medical history | |||
Overnight stay in healthcare facility in previous 12 weeks | 615 (60) | 150 (63.8) | 0.39 |
Diabetes | 432 (41.5) | 91 (38.9) | 0.46 |
Antimicrobial drug use in previous 3 months | 387 (39.2) | 63 (26.9) | < 0.01 |
Cancer | 313 (30.2) | 59 (25.1) | 0.12 |
Congestive heart disease | 305 (29.3) | 64 (27.2) | 0.53 |
CDI in past 5 years | 66 (7.5) | 18 (8.1) | 0.76 |
Dementia | 76 (7.3) | 14 (5.9) | 0.46 |
Inflammatory bowel disease | 65 (6.3) | 10 (4.3) | 0.26 |
Hemiplegia/quadriplegia | 54 (5.2) | 8 (3.4) | 0.25 |
*Values are no. (%) except as indicated. Data are presented in descending order of Study stool specimen collected column. Values of missing or unknown were excluded from percentage and p value calculations. CDI, Clostridioides difficile infection; IQR, interquartile range; SOC, standard-of-care.
1Study results were presented at the annual Anaerobe 2022 Congress, July 28–31, 2022, Seattle, Washington, USA.
2Current affiliation: Norton Healthcare, Louisville, Kentucky, USA.
3Current affiliation: AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.